Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
14370 | 708 | 34.6 | 72% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
286 | 18324 | HYPOTHYROIDISM//CONGENITAL HYPOTHYROIDISM//THYROID HORMONE |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | MT SINAI BONE PROGRAM | Address | 6 | 23% | 3% | 22 |
2 | MOL ENDOCRINOL GRP | Address | 5 | 16% | 4% | 27 |
3 | THYROXINE SUPPRESSIVE THERAPY | Author keyword | 4 | 75% | 0% | 3 |
4 | MOL ENDOCRINOL GRP MED | Address | 3 | 60% | 0% | 3 |
5 | SUPPRESSIVE THERAPY | Author keyword | 2 | 25% | 1% | 6 |
6 | SUBCLINICAL HYPERTHYROIDISM | Author keyword | 2 | 12% | 2% | 12 |
7 | L THYROXINE | Author keyword | 1 | 10% | 2% | 13 |
8 | ICSM MOL ENDOCRINOL GRP | Address | 1 | 50% | 0% | 2 |
9 | MOUSE ZEBRAFISH GENET | Address | 1 | 50% | 0% | 2 |
10 | SANGER MOUSE GENET PROJECT | Address | 1 | 50% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | THYROXINE SUPPRESSIVE THERAPY | 4 | 75% | 0% | 3 | Search THYROXINE+SUPPRESSIVE+THERAPY | Search THYROXINE+SUPPRESSIVE+THERAPY |
2 | SUPPRESSIVE THERAPY | 2 | 25% | 1% | 6 | Search SUPPRESSIVE+THERAPY | Search SUPPRESSIVE+THERAPY |
3 | SUBCLINICAL HYPERTHYROIDISM | 2 | 12% | 2% | 12 | Search SUBCLINICAL+HYPERTHYROIDISM | Search SUBCLINICAL+HYPERTHYROIDISM |
4 | L THYROXINE | 1 | 10% | 2% | 13 | Search L+THYROXINE | Search L+THYROXINE |
5 | ANTITHYROID TREATMENT | 1 | 40% | 0% | 2 | Search ANTITHYROID+TREATMENT | Search ANTITHYROID+TREATMENT |
6 | OLPADRONATE | 1 | 21% | 0% | 3 | Search OLPADRONATE | Search OLPADRONATE |
7 | BENIGN NODULAR GOITRE | 1 | 50% | 0% | 1 | Search BENIGN+NODULAR+GOITRE | Search BENIGN+NODULAR+GOITRE |
8 | CALCITONIN DEFICIENCY | 1 | 50% | 0% | 1 | Search CALCITONIN+DEFICIENCY | Search CALCITONIN+DEFICIENCY |
9 | EXOGENOUS HYPERTHYROIDISM | 1 | 50% | 0% | 1 | Search EXOGENOUS+HYPERTHYROIDISM | Search EXOGENOUS+HYPERTHYROIDISM |
10 | FEMUR DIAPHYSIS | 1 | 50% | 0% | 1 | Search FEMUR+DIAPHYSIS | Search FEMUR+DIAPHYSIS |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | SUBCLINICAL HYPERTHYROIDISM | 22 | 29% | 9% | 65 |
2 | TOTALLY THYROIDECTOMIZED PATIENTS | 21 | 90% | 1% | 9 |
3 | CALCIUM PHOSPHORUS METABOLISM | 21 | 85% | 2% | 11 |
4 | CALCITONIN DEFICIENCY | 15 | 82% | 1% | 9 |
5 | THYROXINE SUPPRESSIVE THERAPY | 15 | 68% | 2% | 13 |
6 | TERM L THYROXINE | 14 | 100% | 1% | 7 |
7 | THYROID HORMONE THERAPY | 13 | 71% | 1% | 10 |
8 | FORMER HYPERTHYROID PATIENTS | 12 | 86% | 1% | 6 |
9 | RECOMBINANT TSH | 11 | 100% | 1% | 6 |
10 | ANTI THYROID TREATMENT | 8 | 100% | 1% | 5 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Mechanisms of action of thyroid hormones in the skeleton | 2013 | 15 | 76 | 58% |
The skeletal consequences of thyrotoxicosis | 2012 | 26 | 111 | 70% |
The effect of thyroid hormone on skeletal integrity | 1999 | 121 | 69 | 77% |
Metabolic and Clinical Consequences of Hyperthyroidism on Bone Density | 2013 | 7 | 93 | 82% |
Thyroid and bone | 2010 | 46 | 91 | 65% |
The thyroid and the skeleton | 2004 | 68 | 103 | 66% |
Critical role of the hypothalamic-pituitary-thyroid axis in bone | 2008 | 39 | 60 | 58% |
Actions of thyroid hormones in bone | 2009 | 21 | 49 | 59% |
Thyroid and bone | 2007 | 20 | 166 | 78% |
The skeletal phenotypes of TR alpha and TR beta mutant mice | 2009 | 18 | 69 | 55% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MT SINAI BONE PROGRAM | 6 | 23% | 3.1% | 22 |
2 | MOL ENDOCRINOL GRP | 5 | 16% | 3.8% | 27 |
3 | MOL ENDOCRINOL GRP MED | 3 | 60% | 0.4% | 3 |
4 | ICSM MOL ENDOCRINOL GRP | 1 | 50% | 0.3% | 2 |
5 | MOUSE ZEBRAFISH GENET | 1 | 50% | 0.3% | 2 |
6 | SANGER MOUSE GENET PROJECT | 1 | 50% | 0.3% | 2 |
7 | SYST BIOL BONE | 1 | 50% | 0.3% | 2 |
8 | ENDOCRINOL F | 1 | 40% | 0.3% | 2 |
9 | ENDOCRINOL METAB 2 | 1 | 27% | 0.4% | 3 |
10 | NUCL MED RADIAT PROTECT PATHOPHYSIOL | 1 | 21% | 0.4% | 3 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000128656 | SUBCLINICAL HYPOTHYROIDISM//HYPOTHYROIDISM//SUBCLINICAL HYPERTHYROIDISM |
2 | 0.0000096339 | RESISTANCE TO THYROID HORMONE//THYROID HORMONE RECEPTOR//V ERBA |
3 | 0.0000091940 | IMMUNE ENDOCRINE//HISTOTYPIC CULTURES//MERVIN BOVAIRD STUDIES MOL BIOL BIOTECHNOL |
4 | 0.0000089637 | DEOXYPYRIDINOLINE//PYRIDINOLINE//OSTEOCALCIN |
5 | 0.0000067919 | SIMULATED HIGH ALTITUDE//ADV STAT//BODY MASS SET POINT |
6 | 0.0000065382 | FAMILIAL DYSALBUMINEMIC HYPERTHYROXINEMIA//THYROID HORMONE AUTOANTIBODIES//FREE THYROXINE |
7 | 0.0000064700 | AROMATASE DEFICIENCY//MALE OSTEOPOROSIS//INTEGRATED MED ENDOCRINOL METAB GERIATR |
8 | 0.0000060864 | ADRENERGIC LIPOLYSIS//BETA CELL GRANULES//BIOL PATHOL FOOD SCI |
9 | 0.0000051676 | HDR SYNDROME//KENNY CAFFEY SYNDROME//HYPOPARATHYROIDISM |
10 | 0.0000051355 | LONGEV SCI//HOSP GERIATR MED//TORAT MED |